Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
474 Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to mitigate irSAEs
Compose a Response to This Article
Other responses
No responses have been published for this article.